{"id":923473,"date":"2026-01-05T07:38:14","date_gmt":"2026-01-05T12:38:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/"},"modified":"2026-01-05T07:38:14","modified_gmt":"2026-01-05T12:38:14","slug":"heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/","title":{"rendered":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><i>HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment<\/i><\/li>\n<li><i>Pivotal Milestone Unlocks Multiple Key Initiatives in Company\u2019s Growth Strategy<\/i><\/li>\n<\/ul>\n<p>SANTA CLARA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=e075c270a068e7c52705ccea1e3747ba\"><b>HeartBeam, Inc.<\/b><\/a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA.<\/p>\n<p>\nHeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site meetings with investors and potential commercialization and co-development partners to discuss the recently announced <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.heartbeam.com%2Fnews-events%2Fpress-releases%2Fdetail%2F107%2Fheartbeam-receives-fda-clearance-for-first-ever-cable-free&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=US+Food+and+Drug+Administration+%28FDA%29+510%28k%29+clearance+for+the+Company%26%238217%3Bs+groundbreaking+12-lead+electrocardiogram+%28ECG%29+synthesis+software&amp;index=2&amp;md5=e3330b801274944aabd88d9841537baa\">US Food and Drug Administration (FDA) 510(k) clearance for the Company\u2019s groundbreaking 12-lead electrocardiogram (ECG) synthesis software<\/a> for the assessment of arrhythmias. Unlike any single-lead or 6-lead consumer device, HeartBeam\u2019s patented cable-free technology captures the heart\u2019s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. This allows patients to obtain an ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind. The synthesized 12-lead ECG is promptly reviewed by an on-demand, board-certified cardiologist.<\/p>\n<p>\nHeartBeam plans to initiate a limited U.S. commercial launch in Q1 2026 with select concierge and preventive cardiology practices that have already signaled strong adoption interest. Additional details on broader geographic rollout, wearable integration, AI-enabled automated insights, and the Company\u2019s heart attack detection program will be announced in the near future.<\/p>\n<p>\nTo schedule an off-site one-on-one meeting with HeartBeam management during the event, please contact MZ Group at <a rel=\"nofollow\" href=\"mailto:BEAT@mzgroup.us\">BEAT@mzgroup.us<\/a>.<\/p>\n<p><b>About HeartBeam, Inc.<\/b><\/p>\n<p>\nHeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care \u2013 all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam\u2019s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025<sup>1<\/sup>. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=HeartBeam.com&amp;index=3&amp;md5=6d9dcacf21b2f2d7bff306148b2923e5\">HeartBeam.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nAll statements in this release that are not based on historical fact are &#8220;forward-looking statements.&#8221; While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=a903d1d81ede78d42f9896a095727993\">www.sec.gov<\/a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.<\/p>\n<p><sup>1<\/sup><b>Cleared Indications for Use<\/b><\/p>\n<p>\nThe HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient\u2019s 3-Lead (in three-directions) electrocardiogram (ECG) acquired from 5 electrodes. The device is intended to be used by adult patients in either a clinical setting or at home. The device does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional.<\/p>\n<p>\nThe HeartBeam 12-Lead ECG Synthesis Software synthesizes a 12-Lead ECG from the HeartBeam System 3-Leads (in three-directions) recording device, producing a visual 12-Lead ECG representation that is similar, but not identical, to the same leads of a standard diagnostic 12-Lead ECG. The synthesized 12-Lead ECG output is solely intended for manual assessment of normal sinus rhythm and the following non-life-threatening arrhythmias: sinus arrhythmia, sinus tachycardia, sinus bradycardia, atrial premature complexes, atrial fibrillation, and ventricular premature complex. The synthesized 12-Lead ECG output is not intended for the assessment of any other arrhythmia or conditions (including but not limited to: other atrial arrhythmias, ventricular arrhythmias, hypertrophy, conduction disorders, myocardial infarction or ischemia, pacemaker functions, localization of arrhythmia foci, ECG wave abnormalities, and\/or any other disorder). The software does not conduct cardiac analysis and is not intended to replace a standard 12-Lead ECG. The 12-Lead ECG Synthesis Software is intended for adult use only.<\/p>\n<p>\nFor full safety information, see the full <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcdn.prod.website-files.com%2F60c8eb9ac80e9635cdb48ef3%2F6939082837e447c905660645_D-10001%2520HeartBeam%2520AIMIGo%2520Patient%2520User%2520Manual%2520%2528Rev6%2529.pdf&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=Instructions+for+Use&amp;index=5&amp;md5=a23537177f0bbbc6feb28c25d0608b00\">Instructions for Use<\/a> or <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fcdn.prod.website-files.com%2F60c8eb9ac80e9635cdb48ef3%2F69390840ce38a322e4a8c400_D-10002%2520HeartBeam%2520AIMIGo%2520Clinician%2520Portal%2520and%2520ECG%2520Viewer%2520User%2520Manual%2520%2528Rev8%2529.pdf&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=Clinician+Portal+Manual&amp;index=6&amp;md5=852593da25a732f615f13583d60ed906\">Clinician Portal Manual<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260105542890\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260105542890\/en\/<\/a><\/span><\/p>\n<p><b>Investor Relations Contact:<br \/>\n<\/b><br \/>Chris Tyson<br \/>\n<br \/>Executive Vice President<br \/>\n<br \/>MZ North America<br \/>\n<br \/>Direct: 949-491-8235<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:BEAT@mzgroup.us\">BEAT@mzgroup.us<br \/>\n<\/a><br \/><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mzgroup.us%2F&amp;esheet=54386370&amp;newsitemid=20260105542890&amp;lan=en-US&amp;anchor=www.mzgroup.us&amp;index=7&amp;md5=729f1309f72a8aa24fff0d55b1c46ba8\">www.mzgroup.us<\/a><\/p>\n<p><b>Media Contact:<br \/>\n<span class=\"bwuline\"><br \/><\/span><\/b><a rel=\"nofollow\" href=\"mailto:media@heartbeam.com\">media@heartbeam.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Cardiology Software Biotechnology Health FDA Medical Devices Health Technology Technology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260105542890\/en\/1903491\/3\/BEAT_Logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key Initiatives in Company\u2019s Growth Strategy SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA. HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site meetings with investors and potential commercialization and co-development partners to discuss the recently &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-923473","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key Initiatives in Company\u2019s Growth Strategy SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA. HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site meetings with investors and potential commercialization and co-development partners to discuss the recently &hellip; Continue reading &quot;HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T12:38:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference\",\"datePublished\":\"2026-01-05T12:38:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/\"},\"wordCount\":943,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/\",\"name\":\"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-01-05T12:38:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk","og_description":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference HeartBeam Recently Received US Food and Drug Administration (FDA) Clearance for First-Ever Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment Pivotal Milestone Unlocks Multiple Key Initiatives in Company\u2019s Growth Strategy SANTA CLARA, Calif.&#8211;(BUSINESS WIRE)&#8211;HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare Conference taking place January 12-15, 2026 at the Westin St. Francis Hotel in San Francisco, CA. HeartBeam Chief Executive Officer, Robert Eno, and Chief Financial Officer, Timothy Cruickshank, will be available January 12-14 for off-site meetings with investors and potential commercialization and co-development partners to discuss the recently &hellip; Continue reading \"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-05T12:38:14+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference","datePublished":"2026-01-05T12:38:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/"},"wordCount":943,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/","name":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-01-05T12:38:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260105542890r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heartbeam-to-attend-jp-morgan-2026-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HeartBeam to Attend JP Morgan 2026 Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=923473"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/923473\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=923473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=923473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=923473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}